166 related articles for article (PubMed ID: 36197786)
1. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms.
Gaspar TB; Lopes JM; Soares P; Vinagre J
Endocr Relat Cancer; 2022 Dec; 29(12):R191-R208. PubMed ID: 36197786
[TBL] [Abstract][Full Text] [Related]
2. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
3. Two well-differentiated pancreatic neuroendocrine tumor mouse models.
Wong C; Tang LH; Davidson C; Vosburgh E; Chen W; Foran DJ; Notterman DA; Levine AJ; Xu EY
Cell Death Differ; 2020 Jan; 27(1):269-283. PubMed ID: 31160716
[TBL] [Abstract][Full Text] [Related]
4. The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.
Pipinikas CP; Berner AM; Sposito T; Thirlwell C
Endocr Relat Cancer; 2019 Aug; 26(9):R519-R544. PubMed ID: 31252410
[TBL] [Abstract][Full Text] [Related]
5. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
Ishida H; Lam AK
Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
[TBL] [Abstract][Full Text] [Related]
7. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract][Full Text] [Related]
8. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
9. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
[No Abstract] [Full Text] [Related]
10. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
11. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification.
Khanna L; Prasad SR; Sunnapwar A; Kondapaneni S; Dasyam A; Tammisetti VS; Salman U; Nazarullah A; Katabathina VS
Radiographics; 2020; 40(5):1240-1262. PubMed ID: 32795239
[TBL] [Abstract][Full Text] [Related]
13. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
14. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
15. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
16. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.
Vandamme T; Beyens M; Boons G; Schepers A; Kamp K; Biermann K; Pauwels P; De Herder WW; Hofland LJ; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Jan; 26(1):1-12. PubMed ID: 30021865
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract][Full Text] [Related]
18. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
[TBL] [Abstract][Full Text] [Related]
19. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
20. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
